Treatment of patients with CLL
presents the summary about registration and reimbursement of substances used in treatment of patients with CLL in Poland and in the UK. In the UK the licensed innovative drugs: ibrutinib, idelalisib, obinutuzumab, ofatumumab, rituximab are reimbursed and venetoclax is recommended by NICE for use within the Cancer Drugs Fund. [7] For comparison, in Poland only three new drugs are reimbursed: ibrutinib (for treatment of relapsed or refractory CLL in patients with presence of 17p deletion or TP53 mutation), obinutuzumab and rituximab. The other two (idelalisib and ofatumumab) are not recommended by President of AOTMiT and venetoclax is under appraisal. Currently, idelalisib is not recommended for reimbursement by President of AOTMiT. President decision is based on the lack of evidence. In case of ofatumumab, the President of AOTMiT taking into account the Transparency Council Statement, available scientific evidences, results of pharmacoeconomic analyses, and national and international guidelines, stated that reimbursement of ofatumumab is unjustified. [8] In Poland, there is a narrow group of patients requiring special treatment due to contraindications against the use of BCRi: ibrutinib, idelasilib (about 25 -26% of patients). [9] It is important to ensure alternative, reimbursed therapeutic options for these patients. Venetoclax has a marketing authorization for the treatment of CLL in patients with the presence of 17p deletion or TP53 mutation who are unsuitable for or have failed a BCRi treatment or for the treatment of CLL in patients with the absence of 17p deletion or TP53 mutation who have failed both chemo-immunotherapy and a BCRi treatment.
Patients with CLL may require hospitalization, which costs in Poland are covered by NHF within JGP groups:
• S02 Haematopoietic and immunological diseases > 10 days, • S03 Haematopoietic and immunological diseases > 1 day, • S04 Haematopoietic and immunological diseases < 2 days. 
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Conclusions
Poland is lagging behind the UK in terms of availability of effective treatment options for patients with CLL. At present, the agestandardized incidence rates of CLL are lower in Poland compared to the UK, however the CLL is a disease of the people aged over 65 years and since the Polish population is aging, we expect that CLL incidence rate will increase in the coming years. Furthermore, 5-years survival rate for patients with CLL in Poland is substantially lower compared to the UK as well as to the average survival in whole of Europe, therefore, it is important for Polish patients gain to access to new therapies to ensure that they are receiving best available treatment.
The age-standardized incidence and mortality rates for both males and females are significantly higher in the UK compared with Poland. According to NCR, the incidence rates of lymphoid leukemia in Poland in 2013 were 5.1 and 3.1 per 100 000 for males and females, respectively ( Figure 1 ) and mortality rates in 2014 were 2.2 for males and 1.0 females per 100 000 inhabitants ( Figure  2 ).
[1] In the UK in 2014 the incidence rates of CLL were 8.3 and 4.1 per 100 000 for males and females, respectively ( Figure 1 ) and mortality rates were 2.6 and 1.2 per 100 000 for males and females, respectively (Figure 2 ).
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